Furthermore, we discovered that decreasing levels of circulating FGF-21 and GDF-15 were associated with greater weight loss at one year regardless of the type of anti-obesity therapies. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.